ALK announces new epinephrine auto-injector strategy based on innovative new product for the USA
(WorldNews Denmark)

ALK`s (ALKB:DC / OMX: ALK B / AKABY / AKBLF) new anaphylaxis strategy is to become a major player in the US epinephrine market based on an exclusive deal with Windgap Medical to launch a next generation epinephrine auto-injector pen. ALK has already begun to support the development and will subsequently be responsible for global commercialisation of the product. The new pen is designed to be small, easy-to-use, heat-stable, and with a long shelf life. The market and customers are well-known to ALK and the strategy builds on the success and learnings from ALK`s current product Jext®, which primarily targets European customers. ALK today announced that it has finalised its strategy for...